Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019.
Identifieur interne : 000226 ( Main/Corpus ); précédent : 000225; suivant : 000227Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019.
Auteurs : Qiuxiang Yang ; Ling Xie ; Wei Zhang ; Lin Zhao ; Huajun Wu ; Jie Jiang ; Jili Zou ; Jianguang Liu ; Jun Wu ; Yonggang Chen ; Jinhu WuSource :
- Journal of clinical pharmacy and therapeutics [ 1365-2710 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Age Factors (MeSH), Aged (MeSH), Antiviral Agents (therapeutic use), Biomarkers (blood), China (epidemiology), Comorbidity (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (mortality), Coronavirus Infections (therapy), Female (MeSH), Glucocorticoids (therapeutic use), Humans (MeSH), Immunologic Factors (therapeutic use), Lymphocyte Count (MeSH), Male (MeSH), Medicine, Chinese Traditional (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (mortality), Pneumonia, Viral (therapy), Prognosis (MeSH), Retrospective Studies (MeSH), Risk Factors (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , blood : Biomarkers.
- chemical , therapeutic use : Antiviral Agents, Glucocorticoids, Immunologic Factors.
- geographic , epidemiology : China.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- mortality : Coronavirus Infections, Pneumonia, Viral.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Adult, Age Factors, Aged, Comorbidity, Female, Humans, Lymphocyte Count, Male, Medicine, Chinese Traditional, Middle Aged, Pandemics, Prognosis, Retrospective Studies, Risk Factors, Treatment Outcome.
Abstract
WHAT IS KNOWN AND OBJECTIVE
Since the December 2019 discovery of several cases of coronavirus disease 2019 (COVID-19) in Wuhan, China, the infection has spread worldwide. Our aim is to report on the clinical characteristics, treatments and prognoses of COVID-19.
METHODS
This was a retrospective, single-centre, case series of 136 patients who were diagnosed with COVID-19 at Wuhan Third Hospital in Wuhan, China, between 28 January 2020 and 12 February 2020. The clinical characteristics, laboratory tests, treatment features and prognoses were summarized.
RESULTS AND DISCUSSION
The 136 patients were divided into a moderate (M) group (n = 103, 75.7%) and a severe and critical (SC) group (n = 33, 24.3%). There were significant differences in the incidences of concomitant chronic medical illnesses (eg, hypertension, diabetes and cardiovascular disease), fever, dry cough and dyspnoea among the two groups (P < .05). Compared with those in the M group, lymphocyte count (LYM) decreased significantly in the SC group, while the serum levels of C-reactive protein (CRP), procalcitonin (PCT), creatinine (Cre), D-dimer, lactic dehydrogenase (LDH), myoglobin (MB) and troponin I (cTnl) increased significantly in the SC group (P < .05). The main therapeutic drugs were antivirals, antibiotics, glucocorticoids, immunomodulators, traditional Chinese medicine preparations and symptomatic support drugs. There were significant differences in the incidences of shock, myocardial injury, acute respiratory distress syndrome (ARDS) and renal injury among the two groups (P < .05). Among the 136 patients, 99 (72.7%) were cured, 14 (10.3%) were transferred to other hospital and 23 (16.9%) died.
WHAT IS NEW AND CONCLUSION
Elderly patients with chronic diseases are more likely to develop severe or critical COVID-19 with multiple organ damage or systemic injuries. The improvement of LYM and CRP may be associated with the prognoses of COVID-19. The combined use of three or more antiviral drugs is to be avoided. The combination of broad-spectrum antibacterial drugs is not recommended and the risk of drug-induced liver injury should be monitored. Throughout a patient's hospitalization, their treatment plan should be evaluated and adjusted according to their vital signs, clinical symptoms, laboratory tests and imaging changes. Patients should receive effective psychological counselling.
DOI: 10.1111/jcpt.13170
PubMed: 32449224
PubMed Central: PMC7283656
Links to Exploration step
pubmed:32449224Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019.</title><author><name sortKey="Yang, Qiuxiang" sort="Yang, Qiuxiang" uniqKey="Yang Q" first="Qiuxiang" last="Yang">Qiuxiang Yang</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Xie, Ling" sort="Xie, Ling" uniqKey="Xie L" first="Ling" last="Xie">Ling Xie</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Wei" sort="Zhang, Wei" uniqKey="Zhang W" first="Wei" last="Zhang">Wei Zhang</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhao, Lin" sort="Zhao, Lin" uniqKey="Zhao L" first="Lin" last="Zhao">Lin Zhao</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wu, Huajun" sort="Wu, Huajun" uniqKey="Wu H" first="Huajun" last="Wu">Huajun Wu</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Jiang, Jie" sort="Jiang, Jie" uniqKey="Jiang J" first="Jie" last="Jiang">Jie Jiang</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zou, Jili" sort="Zou, Jili" uniqKey="Zou J" first="Jili" last="Zou">Jili Zou</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Jianguang" sort="Liu, Jianguang" uniqKey="Liu J" first="Jianguang" last="Liu">Jianguang Liu</name><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wu, Jun" sort="Wu, Jun" uniqKey="Wu J" first="Jun" last="Wu">Jun Wu</name><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Chen, Yonggang" sort="Chen, Yonggang" uniqKey="Chen Y" first="Yonggang" last="Chen">Yonggang Chen</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wu, Jinhu" sort="Wu, Jinhu" uniqKey="Wu J" first="Jinhu" last="Wu">Jinhu Wu</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32449224</idno><idno type="pmid">32449224</idno><idno type="doi">10.1111/jcpt.13170</idno><idno type="pmc">PMC7283656</idno><idno type="wicri:Area/Main/Corpus">000226</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000226</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019.</title><author><name sortKey="Yang, Qiuxiang" sort="Yang, Qiuxiang" uniqKey="Yang Q" first="Qiuxiang" last="Yang">Qiuxiang Yang</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Xie, Ling" sort="Xie, Ling" uniqKey="Xie L" first="Ling" last="Xie">Ling Xie</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Wei" sort="Zhang, Wei" uniqKey="Zhang W" first="Wei" last="Zhang">Wei Zhang</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhao, Lin" sort="Zhao, Lin" uniqKey="Zhao L" first="Lin" last="Zhao">Lin Zhao</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wu, Huajun" sort="Wu, Huajun" uniqKey="Wu H" first="Huajun" last="Wu">Huajun Wu</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Jiang, Jie" sort="Jiang, Jie" uniqKey="Jiang J" first="Jie" last="Jiang">Jie Jiang</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zou, Jili" sort="Zou, Jili" uniqKey="Zou J" first="Jili" last="Zou">Jili Zou</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Jianguang" sort="Liu, Jianguang" uniqKey="Liu J" first="Jianguang" last="Liu">Jianguang Liu</name><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wu, Jun" sort="Wu, Jun" uniqKey="Wu J" first="Jun" last="Wu">Jun Wu</name><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Chen, Yonggang" sort="Chen, Yonggang" uniqKey="Chen Y" first="Yonggang" last="Chen">Yonggang Chen</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wu, Jinhu" sort="Wu, Jinhu" uniqKey="Wu J" first="Jinhu" last="Wu">Jinhu Wu</name><affiliation><nlm:affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of clinical pharmacy and therapeutics</title><idno type="eISSN">1365-2710</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Age Factors (MeSH)</term><term>Aged (MeSH)</term><term>Antiviral Agents (therapeutic use)</term><term>Biomarkers (blood)</term><term>China (epidemiology)</term><term>Comorbidity (MeSH)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (mortality)</term><term>Coronavirus Infections (therapy)</term><term>Female (MeSH)</term><term>Glucocorticoids (therapeutic use)</term><term>Humans (MeSH)</term><term>Immunologic Factors (therapeutic use)</term><term>Lymphocyte Count (MeSH)</term><term>Male (MeSH)</term><term>Medicine, Chinese Traditional (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (mortality)</term><term>Pneumonia, Viral (therapy)</term><term>Prognosis (MeSH)</term><term>Retrospective Studies (MeSH)</term><term>Risk Factors (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Glucocorticoids</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>China</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Comorbidity</term><term>Female</term><term>Humans</term><term>Lymphocyte Count</term><term>Male</term><term>Medicine, Chinese Traditional</term><term>Middle Aged</term><term>Pandemics</term><term>Prognosis</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>WHAT IS KNOWN AND OBJECTIVE</b></p><p>Since the December 2019 discovery of several cases of coronavirus disease 2019 (COVID-19) in Wuhan, China, the infection has spread worldwide. Our aim is to report on the clinical characteristics, treatments and prognoses of COVID-19.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>This was a retrospective, single-centre, case series of 136 patients who were diagnosed with COVID-19 at Wuhan Third Hospital in Wuhan, China, between 28 January 2020 and 12 February 2020. The clinical characteristics, laboratory tests, treatment features and prognoses were summarized.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS AND DISCUSSION</b></p><p>The 136 patients were divided into a moderate (M) group (n = 103, 75.7%) and a severe and critical (SC) group (n = 33, 24.3%). There were significant differences in the incidences of concomitant chronic medical illnesses (eg, hypertension, diabetes and cardiovascular disease), fever, dry cough and dyspnoea among the two groups (P < .05). Compared with those in the M group, lymphocyte count (LYM) decreased significantly in the SC group, while the serum levels of C-reactive protein (CRP), procalcitonin (PCT), creatinine (Cre), D-dimer, lactic dehydrogenase (LDH), myoglobin (MB) and troponin I (cTnl) increased significantly in the SC group (P < .05). The main therapeutic drugs were antivirals, antibiotics, glucocorticoids, immunomodulators, traditional Chinese medicine preparations and symptomatic support drugs. There were significant differences in the incidences of shock, myocardial injury, acute respiratory distress syndrome (ARDS) and renal injury among the two groups (P < .05). Among the 136 patients, 99 (72.7%) were cured, 14 (10.3%) were transferred to other hospital and 23 (16.9%) died.</p></div><div type="abstract" xml:lang="en"><p><b>WHAT IS NEW AND CONCLUSION</b></p><p>Elderly patients with chronic diseases are more likely to develop severe or critical COVID-19 with multiple organ damage or systemic injuries. The improvement of LYM and CRP may be associated with the prognoses of COVID-19. The combined use of three or more antiviral drugs is to be avoided. The combination of broad-spectrum antibacterial drugs is not recommended and the risk of drug-induced liver injury should be monitored. Throughout a patient's hospitalization, their treatment plan should be evaluated and adjusted according to their vital signs, clinical symptoms, laboratory tests and imaging changes. Patients should receive effective psychological counselling.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32449224</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2710</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of clinical pharmacy and therapeutics</Title><ISOAbbreviation>J Clin Pharm Ther</ISOAbbreviation></Journal><ArticleTitle>Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019.</ArticleTitle><Pagination><MedlinePgn>609-616</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jcpt.13170</ELocationID><Abstract><AbstractText Label="WHAT IS KNOWN AND OBJECTIVE" NlmCategory="OBJECTIVE">Since the December 2019 discovery of several cases of coronavirus disease 2019 (COVID-19) in Wuhan, China, the infection has spread worldwide. Our aim is to report on the clinical characteristics, treatments and prognoses of COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a retrospective, single-centre, case series of 136 patients who were diagnosed with COVID-19 at Wuhan Third Hospital in Wuhan, China, between 28 January 2020 and 12 February 2020. The clinical characteristics, laboratory tests, treatment features and prognoses were summarized.</AbstractText><AbstractText Label="RESULTS AND DISCUSSION" NlmCategory="CONCLUSIONS">The 136 patients were divided into a moderate (M) group (n = 103, 75.7%) and a severe and critical (SC) group (n = 33, 24.3%). There were significant differences in the incidences of concomitant chronic medical illnesses (eg, hypertension, diabetes and cardiovascular disease), fever, dry cough and dyspnoea among the two groups (P < .05). Compared with those in the M group, lymphocyte count (LYM) decreased significantly in the SC group, while the serum levels of C-reactive protein (CRP), procalcitonin (PCT), creatinine (Cre), D-dimer, lactic dehydrogenase (LDH), myoglobin (MB) and troponin I (cTnl) increased significantly in the SC group (P < .05). The main therapeutic drugs were antivirals, antibiotics, glucocorticoids, immunomodulators, traditional Chinese medicine preparations and symptomatic support drugs. There were significant differences in the incidences of shock, myocardial injury, acute respiratory distress syndrome (ARDS) and renal injury among the two groups (P < .05). Among the 136 patients, 99 (72.7%) were cured, 14 (10.3%) were transferred to other hospital and 23 (16.9%) died.</AbstractText><AbstractText Label="WHAT IS NEW AND CONCLUSION" NlmCategory="CONCLUSIONS">Elderly patients with chronic diseases are more likely to develop severe or critical COVID-19 with multiple organ damage or systemic injuries. The improvement of LYM and CRP may be associated with the prognoses of COVID-19. The combined use of three or more antiviral drugs is to be avoided. The combination of broad-spectrum antibacterial drugs is not recommended and the risk of drug-induced liver injury should be monitored. Throughout a patient's hospitalization, their treatment plan should be evaluated and adjusted according to their vital signs, clinical symptoms, laboratory tests and imaging changes. Patients should receive effective psychological counselling.</AbstractText><CopyrightInformation>© 2020 John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qiuxiang</ForeName><Initials>Q</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-6134-0653</Identifier><AffiliationInfo><Affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>HuaJun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Jili</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianguang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yonggang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jinhu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pharmaceutical Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infections Department, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Clin Pharm Ther</MedlineTA><NlmUniqueID>8704308</NlmUniqueID><ISSNLinking>0269-4727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008516" MajorTopicYN="N">Medicine, Chinese Traditional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical characteristics</Keyword><Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">drug treatment</Keyword><Keyword MajorTopicYN="N">drug-induced liver injury</Keyword><Keyword MajorTopicYN="N">prognoses</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>03</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32449224</ArticleId><ArticleId IdType="doi">10.1111/jcpt.13170</ArticleId><ArticleId IdType="pmc">PMC7283656</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>New coronavirus pneumonia diagnosis and treatment program (7th ed.) (in Chinese). 2020. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml. Accessed March 3, 2020.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.</Citation></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2002032</Citation></Reference><Reference><Citation>Wang DW, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. https://doi.org/10.1001/jama.2020.1585</Citation></Reference><Reference><Citation>Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513.</Citation></Reference><Reference><Citation>Meyer IS, Goetzke CC, Kespohl M, et al. Silencing the CSF-1 Axis using nanoparticle encapsulated siRNA mitigates viral and autoimmune myocarditis [J]. Front Immunol. 2018;9:2303.</Citation></Reference><Reference><Citation>Van Der Poll T, Levi M. Crosstalk between inflammation and coagulation: the lessons of sepsis [J]. Curr Vasc Pharmacol. 2012;10(5):632-638.</Citation></Reference><Reference><Citation>Sutherl MR, Ruf W, Pryzdial EL. Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease-activated receptor 2 cofactors that enhance infection [J]. Blood. 2012;119(15):3638-3645.</Citation></Reference><Reference><Citation>Isinori AM, Minnetti M, Sbardella E, et al. Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect [J]. Eur J Endocrinol. 2015;173(3):R101-R113.</Citation></Reference><Reference><Citation>Haitung HP, Mouthon L, Ahmed R, et al. Clinical applications of intravenous immunoglobulins(IVIg)-beyond immunodeficiencies and neurology [J]. Clin Exp Immunol. 2009;158(s1):23-33.</Citation></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239.</Citation></Reference><Reference><Citation>Nori S, Nebesio C, Brashear R, et al. Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure [J]. Arch Dermatol. 2004;140(12):1537-1538.</Citation></Reference><Reference><Citation>Cottin J, Pierre S, Pizzoglio V, et al. Methylprednisolone-related liver injury: a descriptive study using the French pharmacovigi lance database [J]. Clin Res Hepatol Gastroenterol. 2020. https://doi.org/10.1016/j.clinre.2019.12.008</Citation></Reference><Reference><Citation>Lei XH, Li J, Tang J, et al. Introduction of EASL clinical guideline: drug-induced liver injury [J]. Liver. 2019;24(4):339-348.</Citation></Reference><Reference><Citation>Chai XQ, Hu LF, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause Li2ver damage after 2019-nCoV infection. BioRxiv. 2020. https://doi.org/10.1101/2020.02.03.931766</Citation></Reference><Reference><Citation>Xu Z, Shi Z, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet. 2020;8:420-422.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000226 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000226 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CardioCovidV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32449224
|texte= Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32449224" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CardioCovidV1
| This area was generated with Dilib version V0.6.35. |  |